Emilda Thompson

1.5k total citations
7 papers, 766 citations indexed

About

Emilda Thompson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Emilda Thompson has authored 7 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Emilda Thompson's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Cancer, Lipids, and Metabolism (2 papers). Emilda Thompson is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Cancer, Lipids, and Metabolism (2 papers). Emilda Thompson collaborates with scholars based in United Kingdom, Australia and United States. Emilda Thompson's co-authors include Johann S. de Bono, Gerhardt Attard, Nikhil Babu Oommen, Elizabeth Folkerd, Mitch Dowsett, Alison Reid, David Olmos, Gal Maier, L. Rhoda Molife and Amy Mulick and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and European Urology.

In The Last Decade

Emilda Thompson

7 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emilda Thompson United Kingdom 4 658 292 223 178 164 7 766
S. Settatree United Kingdom 5 572 0.9× 271 0.9× 194 0.9× 170 1.0× 149 0.9× 10 702
Mary Barrett United Kingdom 4 589 0.9× 275 0.9× 226 1.0× 327 1.8× 160 1.0× 7 923
Nikhil Babu Oommen United Kingdom 6 904 1.4× 383 1.3× 366 1.6× 255 1.4× 212 1.3× 7 1.1k
Gal Maier United Kingdom 3 659 1.0× 204 0.7× 235 1.1× 142 0.8× 229 1.4× 5 713
Nicholas I. Simon United States 11 521 0.8× 178 0.6× 253 1.1× 240 1.3× 75 0.5× 31 720
Mohammad Alyamani United States 13 522 0.8× 317 1.1× 142 0.6× 219 1.2× 84 0.5× 19 709
Stephen Balk United States 6 720 1.1× 295 1.0× 436 2.0× 458 2.6× 96 0.6× 8 1.0k
Ellen S. de Morrée Netherlands 8 394 0.6× 69 0.2× 179 0.8× 154 0.9× 173 1.1× 10 544
Oliver Sartor United States 10 346 0.5× 120 0.4× 98 0.4× 97 0.5× 64 0.4× 22 437
Avery Spitz United States 4 380 0.6× 155 0.5× 79 0.4× 180 1.0× 56 0.3× 12 484

Countries citing papers authored by Emilda Thompson

Since Specialization
Citations

This map shows the geographic impact of Emilda Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emilda Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emilda Thompson more than expected).

Fields of papers citing papers by Emilda Thompson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emilda Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emilda Thompson. The network helps show where Emilda Thompson may publish in the future.

Co-authorship network of co-authors of Emilda Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Emilda Thompson. A scholar is included among the top collaborators of Emilda Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emilda Thompson. Emilda Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Molife, L. Rhoda, Aurelius Omlin, Robert J. Jones, et al.. (2014). Randomized Phase II Trial of Nintedanib, Afatinib and Sequential Combination in Castration-Resistant Prostate Cancer. Future Oncology. 10(2). 219–231. 30 indexed citations
2.
Omlin, Aurelius, Carmel Pezaro, Deborah Mukherji, et al.. (2013). Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. European Urology. 64(2). 300–306. 69 indexed citations
3.
Bianchini, Diletta, Shahneen Sandhu, Amy Mulick, et al.. (2012). Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).. Journal of Clinical Oncology. 30(15_suppl). 4553–4553. 2 indexed citations
4.
Pezaro, Carmel, Aurelius Omlin, Deborah Mukherji, et al.. (2012). Survival in metastatic castration resistant prostate cancer (mCRPC) trial participants.. Journal of Clinical Oncology. 30(15_suppl). e15136–e15136. 1 indexed citations
5.
Attard, Gerhardt, Alison Reid, Richard J. Auchus, et al.. (2011). Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer. The Journal of Clinical Endocrinology & Metabolism. 97(2). 507–516. 215 indexed citations
6.
Attard, Gerhardt, Alison Reid, Roger A’Hern, et al.. (2009). Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 27(23). 3742–3748. 448 indexed citations
7.
Attard, Gerhardt, Alison Reid, Rajesh Kumar Sinha, et al.. (2007). Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC). Molecular Cancer Therapeutics. 6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Settatree Breakdown of academic impact, for papers by Mary Barrett Breakdown of academic impact, for papers by Nikhil Babu Oommen Breakdown of academic impact, for papers by Gal Maier Breakdown of academic impact, for papers by Nicholas I. Simon Breakdown of academic impact, for papers by Mohammad Alyamani Breakdown of academic impact, for papers by Stephen Balk Breakdown of academic impact, for papers by Ellen S. de Morrée Breakdown of academic impact, for papers by Oliver Sartor Breakdown of academic impact, for papers by Avery Spitz
Rankless by CCL
2026